Alexander W Kay1, Nicholas L Bayless2, Julia Fukuyama3, Natali Aziz4, Cornelia L Dekker1, Sally Mackey1, Gary E Swan5, Mark M Davis6, Catherine A Blish7. 1. Department of Pediatrics. 2. Stanford Immunology, Stanford University School of Medicine. 3. Department of Statistics, Stanford University. 4. Department of Obstetrics & Gynecology. 5. Stanford Prevention Research Center, Department of Medicine. 6. Stanford Immunology, Stanford University School of Medicine Department of Microbiology & Immunology. 7. Stanford Immunology, Stanford University School of Medicine Department of Medicine, Stanford University School of Medicine, California.
Abstract
BACKGROUND: Inactivated influenza vaccine (IIV) is recommended during pregnancy to prevent influenza infection and its complications in pregnant women and their infants. However, the extent to which pregnancy modifies the antibody response to vaccination remains unclear, and prior studies have focused primarily on hemagglutinin inhibition (HI) titers. A more comprehensive understanding of how pregnancy modifies the humoral immune response to influenza vaccination will aid in maximizing vaccine efficacy. METHODS: Healthy pregnant women and control women were studied prior to, 7 days after, and 28 days after vaccination with IIV. HI titers, microneutralization (MN) titers, and the frequency of circulating plasmablasts were evaluated in pregnant versus control women. RESULTS: Pregnant women and control women mount similarly robust serologic immune responses to IIV, with no significant differences for any influenza strain in postvaccination geometric mean HI or MN titers. HI and MN titers correlate, though MN titers demonstrate more robust changes pre- versus postvaccination. The induction of circulating plasmablasts is increased in pregnant women versus controls (median fold-change 2.60 vs 1.49 [interquartile range, 0.94-7.53 vs 0.63-2.67]; P = .03). CONCLUSIONS: Pregnant women do not have impaired humoral immune responses to IIV and may have increased circulating plasmablast production compared to control women.
BACKGROUND: Inactivated influenza vaccine (IIV) is recommended during pregnancy to prevent influenza infection and its complications in pregnant women and their infants. However, the extent to which pregnancy modifies the antibody response to vaccination remains unclear, and prior studies have focused primarily on hemagglutinin inhibition (HI) titers. A more comprehensive understanding of how pregnancy modifies the humoral immune response to influenza vaccination will aid in maximizing vaccine efficacy. METHODS: Healthy pregnant women and control women were studied prior to, 7 days after, and 28 days after vaccination with IIV. HI titers, microneutralization (MN) titers, and the frequency of circulating plasmablasts were evaluated in pregnant versus control women. RESULTS: Pregnant women and control women mount similarly robust serologic immune responses to IIV, with no significant differences for any influenza strain in postvaccination geometric mean HI or MN titers. HI and MN titers correlate, though MN titers demonstrate more robust changes pre- versus postvaccination. The induction of circulating plasmablasts is increased in pregnant women versus controls (median fold-change 2.60 vs 1.49 [interquartile range, 0.94-7.53 vs 0.63-2.67]; P = .03). CONCLUSIONS: Pregnant women do not have impaired humoral immune responses to IIV and may have increased circulating plasmablast production compared to control women.
Authors: Katherine A Poehling; Peter G Szilagyi; Mary A Staat; Beverly M Snively; Daniel C Payne; Carolyn B Bridges; Susan Y Chu; Laney S Light; Mila M Prill; Lyn Finelli; Marie R Griffin; Kathryn M Edwards Journal: Am J Obstet Gynecol Date: 2011-02-23 Impact factor: 8.661
Authors: Sanae Sasaki; Meghan Sullivan; Carlos F Narvaez; Tyson H Holmes; David Furman; Nai-Ying Zheng; Madhuri Nishtala; Jens Wrammert; Kenneth Smith; Judith A James; Cornelia L Dekker; Mark M Davis; Patrick C Wilson; Harry B Greenberg; Xiao-Song He Journal: J Clin Invest Date: 2011-07-25 Impact factor: 14.808
Authors: Amir Horowitz; Dara M Strauss-Albee; Michael Leipold; Jessica Kubo; Neda Nemat-Gorgani; Ozge C Dogan; Cornelia L Dekker; Sally Mackey; Holden Maecker; Gary E Swan; Mark M Davis; Paul J Norman; Lisbeth A Guethlein; Manisha Desai; Peter Parham; Catherine A Blish Journal: Sci Transl Med Date: 2013-10-23 Impact factor: 17.956
Authors: Elizabeth P Schlaudecker; Monica M McNeal; Caitlin N Dodd; Joseph B Ranz; Mark C Steinhoff Journal: J Infect Dis Date: 2012-09-14 Impact factor: 5.226
Authors: Rachel Finck; Erin F Simonds; Astraea Jager; Smita Krishnaswamy; Karen Sachs; Wendy Fantl; Dana Pe'er; Garry P Nolan; Sean C Bendall Journal: Cytometry A Date: 2013-03-19 Impact factor: 4.355
Authors: Helder I Nakaya; Jens Wrammert; Eva K Lee; Luigi Racioppi; Stephanie Marie-Kunze; W Nicholas Haining; Anthony R Means; Sudhir P Kasturi; Nooruddin Khan; Gui-Mei Li; Megan McCausland; Vibhu Kanchan; Kenneth E Kokko; Shuzhao Li; Rivka Elbein; Aneesh K Mehta; Alan Aderem; Kanta Subbarao; Rafi Ahmed; Bali Pulendran Journal: Nat Immunol Date: 2011-07-10 Impact factor: 25.606
Authors: Thomas A Kraus; Stephanie M Engel; Rhoda S Sperling; Lisa Kellerman; Yungtai Lo; Sylvan Wallenstein; Maria M Escribese; Jose L Garrido; Tricia Singh; Martine Loubeau; Thomas M Moran Journal: J Clin Immunol Date: 2011-12-24 Impact factor: 8.317
Authors: Z Zhong; M Haltalli; B Holder; T Rice; B Donaldson; M O'Driscoll; K Le-Doare; B Kampmann; J S Tregoning Journal: Clin Exp Immunol Date: 2018-12-02 Impact factor: 4.330